HGH Fragment 176-191 2mg

Fragment 176-191 is a synthetic peptide derived from amino acids 176-191 of human growth hormone (hGH). As one of several synthetic C-terminal fragments of hGH studied in rodent models, it has demonstrated potential benefits such as lowering blood sugar without increasing IGF-1 or affecting insulin sensitivity—side effects commonly associated with hGH therapy【1】.

While research specific to fragment 176-191 is limited, studies on the structurally similar peptide AOD9604 (fragment 177-191) offer insights into its potential mechanism of action, benefits, and safety profile【2】.

What Does Fragment 176-191 Do?

The precise mechanism of action of fragment 176-191 remains unclear. However, its effects are believed to parallel those of AOD9604, a low-affinity agonist of the growth hormone (GH) receptor. AOD9604 retains certain GH functions, such as promoting cartilage metabolism and fat loss, without causing the pro-tumor or pro-diabetic effects associated with traditional GH injections【3】.

As a GH receptor agonist, AOD9604 binds to GH receptors to:

• Induce fat metabolism.
• Increase energy consumption and fat oxidation.
• Stimulate the formation of myoblasts (muscle progenitor cells).

Fragment 176-191 is believed to function similarly, supporting its reputation as the “lipolytic fragment” of HGH due to its fat-burning effects observed in preclinical studies【1】.

Fragment 176-191: Benefits and Clinical Insights

1. Fat-Burning Effects

Fragment 176-191 has demonstrated significant fat-reduction effects in rodent models:

• Rodent Study on AOD9604 (2001):
  AOD9604 administration reduced body weight and fat in obese mice over 14 days. The peptide increased beta-3 adrenergic receptor (ADRB3) production, essential for fat metabolism. Notably, this effect was absent in lean mice and mice genetically lacking ADRB3【6】.

These findings suggest fragment 176-191 may target a secondary pathway for fat metabolism that becomes less active as body weight normalizes.

2. Potential in Diabetes Management

Fragment 176-191 shows promise for managing prediabetes and type 2 diabetes:

• Animal Research:
  Studies on various hGH fragments (172-191, 176-191, 177-191, etc.) found the hypoglycemic effect primarily linked to the C-terminal region. Among the fragments tested, fragment 176-191 was the most effective at reducing blood sugar. Secondary benefits included sustained increases in plasma insulin and reduced insulin sensitivity【1】.

3. Cartilage Regeneration

Preliminary evidence suggests fragment 176-191 may promote cartilage repair:

• Rabbit Study on AOD9604 (2015):
  In a model of knee osteoarthritis, AOD9604 combined with hyaluronic acid (HA) enhanced cartilage regeneration. The combination outperformed either AOD9604 or HA alone【7】.

These findings indicate fragment 176-191 may offer similar benefits, potentially aiding in advanced osteoarthritis treatments or reducing the need for surgery.

Side Effects of Fragment 176-191

No clinical studies have been conducted specifically on fragment 176-191, and its side effects remain largely unknown. However, data from AOD9604 trials provide valuable context:

• General Safety:
  AOD9604 trials reported no significant side effects typically associated with hGH, such as insulin resistance, hypertension, or increased IGF-1 levels.
• Reported Adverse Events (AEs):
  In a dose-escalation study of AOD9604 in healthy male subjects, 12 out of 15 participants reported mild AEs, including:

• • Headache: 6 occurrences
  • Fatigue: 4 occurrences
  • Hypoglycemia (unspecified): 3 occurrences
  • Dizziness: 3 occurrences
  • Additional single reports of lethargy, abdominal pain, sore throat, injection site reactions, and seasonal rhinitis【8】.

Overall, AOD9604 was well-tolerated at doses ranging from 25 µg to 400 µg/kg body weight. Researchers noted its safety profile was comparable to rhGH and placebo.

Conclusion

Fragment 176-191 is a promising peptide with potential applications in fat loss, diabetes management, and cartilage regeneration. While direct clinical evidence is limited, studies on the closely related AOD9604 offer compelling insights into its mechanism, benefits, and safety profile. Researchers are encouraged to further explore fragment 176-191 to unlock its full therapeutic potential.

References

1. Mahiques-Santos L. Melanotan [Melanotan]. Actas Dermosifiliogr. 2012 May;103(4):257-9. Spanish. doi: 10.1016/j.ad.2011.08.002. Epub 2011 Nov 1. PMID: 22051769.
2. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006 Apr;27(4):921-30. doi: 10.1016/j.peptides.2005.01.029. Epub 2006 Jan 18. PMID: 16412534.
3. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, Alberts DS. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004 Jul;140(7):827-35. doi: 10.1001/archderm.140.7.827. PMID: 15262693.
4. Brennan, R., Wells, J. G., & Van Hout, M. C. (2014). An unhealthy glow? A review of melanotan use and associated clinical outcomes. Performance Enhancement & Health, 3(2), 78–92.
5. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. doi: 10.1016/0024-3205(96)00160-9. PMID: 8637402.
6. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. doi: 10.1038/sj.ijir.3900582. PMID: 11035391.
7. Giuliano F, Clément P, Droupy S, Alexandre L, Bernabé J. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301. doi: 10.1016/j.neuroscience.2005.11.008. Epub 2005 Dec 19. PMID: 16360286.
8. Minakova E, Lang J, Medel-Matus JS, Gould GG, Reynolds A, Shin D, Mazarati A, Sankar R. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS One. 2019 Jan 10;14(1):e0210389. doi: 10.1371/journal.pone.0210389. PMID: 30629642; PMCID: PMC6328175.
9. Cousen P, Colver G, Helbling I. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. 2009 Sep;161(3):707-8. doi: 10.1111/j.1365-2133.2009.09362.x. Epub 2009 Jul 2. PMID: 19575725.
10. Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’? Br J Dermatol. 2010 Sep;163(3):451-5. doi: 10.1111/j.1365-2133.2010.09891.x. Epub 2010 Jun 9. PMID: 20545686.
11. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ. 2009 Feb 17;338:b566. doi: 10.1136/bmj.b566. PMID: 19224885.
12. Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed “sun tan jab”. BMJ. 2009 Jan 27;338:b277. doi: 10.1136/bmj.b277. PMID: 19174439.
13. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019 Feb 21;12(2):e227644. doi: 10.1136/bcr-2018-227644. PMID: 30796078; PMCID: PMC6388891.